Please login to the form below

Not currently logged in
Email:
Password:

DPP-4

This page shows the latest DPP-4 news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk gets FDA okay for new diabetes hope

Novo Nordisk gets FDA okay for new diabetes hope

In the Pioneer programme, people treated with oral semaglutide achieved greater blood glucose reductions compared to Merck &Co's DPP-4 inhibitor Januvia(sitagliptin), Boehringer Ingelheim and Eli Lilly's SGLT2

Latest news

  • Novo’s diabetes pill defeats Merck’s Januvia in trial Novo’s diabetes pill defeats Merck’s Januvia in trial

    Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... PIONEER 4 saw the enrolment of 711 people with type 2 diabetes

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Merck and Pfizer are hoping that Steglujan will benefit from piggy-backing on Merck’s Januvia - the top-selling DPP-4 inhibitor - backed by some strong clinical data for the combination ... which as yet is the only fixed-dose SGLT2/DPP-4 inhibitor

  • FDA panel backs CV claims for Novo Nordisk's Victoza FDA panel backs CV claims for Novo Nordisk's Victoza

    Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.

  • FDA won't add outcomes data to Januvia label FDA won't add outcomes data to Januvia label

    The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying ... It also found no

  • Boehringer Ingelheim calls for Boehringer Ingelheim calls for "strong and united" Europe

    The pharma unit benefited from a tighter focus on prescription drugs, with sales last year rising 7.4% to 12bn. ... In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of

More from news
Approximately 5 fully matching, plus 75 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    This acquisition brings a phase I oral DPP 4, evogliptin, and an immunomodulator, cenicriviroc (CVC), for treating non-alcoholic steatohepatitis (NASH). ... OncoImmune / Pfizer. Option agreement. Exclusive option to ONC-392 a preclinical CTLA-4 candidate.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    Boehringer's interest in the area is a relatively recent one and is focused on its major partnership with Lilly, which so far has produced Trajenta – a DPP-4 inhibitor for

  • Pharma deals during April 2013 Pharma deals during April 2013

    standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics